Indaptus Therapeutics
Business Services · New York, United States · <25 Employees
View Company Info for Free
About
Headquarters
3 Columbus Cir Fl 15, New York City, New York, ...Phone Number
(646) 427-2727Website
www.indaptusrx.comRevenue
<$5 MillionStock Symbol
INDPIndustry
Most Recent Scoops
Who is Indaptus Therapeutics
Indaptus Therapeutics Org Chart
Is Indaptus Therapeutics your ideal customer?
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check if Indaptus Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Indaptus Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Indaptus Therapeutics had a recent Job posting/layoffs
Check out if Indaptus Therapeutics is spiking on competitors!
Earning: See what the market has to say on Indaptus Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Indaptus Therapeutics
Funding: Get notified immidiatlly once Indaptus Therapeutics has new funding data
Product Launch: Get notified when Indaptus Therapeutics launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Indaptus Therapeutics
Compare insights from companies similar to Indaptus Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Indaptus Therapeutics Employee Growth Rate
Percentage of growth
1st year Mask
2nd year Mask
Indaptus Therapeutics Tech Stack
A closer look at the technologies used by Indaptus Therapeutics
Most Recent Scoops
Indaptus Therapeutics News & Media
Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced financial results for the third quarter ended September 30, 2024, and provided a corporate update.Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology
Preclinical data demonstrates Decoy platform single agent anti-tumor activity and combination-mediated tumor eradication with NSAID, anti-PD1 checkpoint therapy, low dose chemotherapy (LDC) and/or targeted antibody therapy Preclinical data demonstrates Decoy platform single agent anti-tumor activity and combination-mediated tumor eradication with NSAID, anti-PD1 checkpoint therapy, low dose chemotherapy (LDC) and/or targeted antibody therapyIndaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting
Data further confirms Company’s “Pulse-Prime” hypothesis Data further confirms Company’s “Pulse-Prime” hypothesisIndaptus Therapeutics to Present at Two Upcoming Investor Conferences
NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present at two upcoming investor conferences:
Top Companies in United States
Top 10 companies in United States by revenue
Top 10 companies in United States by number of employees
Top 10 companies in United States by total funding amount
Frequently Asked Questions Regarding Indaptus Therapeutics
Indaptus Therapeutics is a biotechnology company developing a proprietary platform that exploits bacterias natural ability to activate both innate and adaptive cellular immune pathways. The company is based in New York, New York.... Read More